Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: A preliminary report of a phase III, randomized, controlled clinical trial.
Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Rong Guo(Sun Yat-sen University), Yihong Ling(Sun Yat-sen University), Wenping Lin(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Zhixing Guo(Sun Yat-sen University), Yuhua Wen(Tongji University), Li Xu(Fujian Medical University), Lianghe Lu(Sun Yat-sen University), Minshan Chen(Sun Yat-sen University), Jingwen Zou(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Qiaoxuan Wang(Institute of Polymers)
Cited by 11
Related Papers
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216